Malgorzata Ciepielewska

Jersey City Medical Center — United States

Medicine · Health Sciences

2h-index60citations25works0.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Amyotrophic Lateral Sclerosis Research(20), Parkinson's Disease Mechanisms and Treatments(7), Neurogenetic and Muscular Disorders Research(6), Health Systems, Economic Evaluations, Quality of Life(3), Porphyrin Metabolism and Disorders(3)

Publications25 total

Survival of Intravenous Edaravone–Treated Patients With <scp>ALS</scp> : Evidence From Administrative Claims Analyses
Muscle & Nerve·2026Open Access
Value of Clinical Evidence and Health Economics and Outcomes Research ( <scp>HEOR</scp> ) Studies
Muscle & Nerve·2026Open Access
Assessing healthcare resource utilization burden and unmet treatment needs in patients with Parkinson’s disease: results from a real-world study
Journal of Comparative Effectiveness Research·2025Open Access
Real-world safety and tolerability of intravenous edaravone in patients with amyotrophic lateral sclerosis
Neurodegenerative Disease Management·2025Open Access
HSD16 Describing the Amyotrophic Lateral Sclerosis US Population and Use of Supportive Aids and Interventions: Results from a Real-World Survey
Value in Health·2025
Evolution of the Treatment Landscape for Patients Diagnosed with Amyotrophic Lateral Sclerosis in the United States (P9-2.006)
Neurology·2025
Treatment of Amyotrophic Lateral Sclerosis in General and Specialist US Healthcare Settings: Results From a Real-World Survey (P8-2.012)
Neurology·2025
Referral Patterns for Patients With Amyotrophic Lateral Sclerosis Enrolled in a US-Based Administrative Claims Database (P8-2.009)
Neurology·2025
Longer disease progression milestone-free time in people with amyotrophic lateral sclerosis treated versus not treated with intravenous edaravone: results from an administrative claims analysis
Journal of Comparative Effectiveness Research·2025· 2 citedOpen Access
Real‐world assessment of the patient profile, clinical characteristics, treatment patterns, and outcomes associated with erythropoietic and X‐linked protoporphyria
The Journal of Dermatology·2025· 2 citedOpen Access
CO151 A Preliminary Analysis of Oral Edaravone-Treated Patients With Amyotrophic Lateral Sclerosis Enrolled in a US-Based Administrative Claims Database
Value in Health·2024Open Access
A Preliminary Analysis of Oral Edaravone-treated Patients with Amyotrophic Lateral Sclerosis Enrolled in a US-based Administrative Claims Database (S3.005)
Neurology·2024
Longer milestone-free time in IV edaravone–treated vs non–IV edaravone-treated patients with amyotrophic lateral sclerosis: An administrative claims analysis
Journal of the Neurological Sciences·2023Open Access
Treatment outcomes for patients with amyotrophic lateral sclerosis receiving intravenous edaravone from a home and alternative-site infusion provider
Journal of the Neurological Sciences·2023
EE522 Healthcare Resource Use and Costs Among Patients with Erythropoietic Protoporphyria and X-Linked Protoporphyria in the United States
Value in Health·2023Open Access
Longer Milestone-Free Time in Patients With Amyotrophic Lateral Sclerosis Treated With IV Edaravone vs Not Treated With IV Edaravone: Results From a US Administrative Claims Analysis (S14.007)
Neurology·2023
Treatment Outcomes for Patients With Amyotrophic Lateral Sclerosis Receiving Intravenous Edaravone From a Home and Alternative-Site Infusion Provider (P6-4.005)
Neurology·2023
Intravenous edaravone treatment in ALS and survival: An exploratory, retrospective, administrative claims analysis
EClinicalMedicine·2022· 51 citedOpen Access
Quantifying the Value of Introducing an Oral Drug Delivery Option for Edaravone: A Review of Analyses Evaluating the Economic Impact of Oral versus Intravenous Formulations
ClinicoEconomics and Outcomes Research·2022· 5 citedOpen Access
EE60 A Review of Analyses Evaluating the Economic Impact of Oral Versus Intravenous Formulations
Value in Health·2022Open Access
page 1 of 2Next →

Frequent Co-authors

Ying Liu(9), Jeffrey Zhang(7), Melissa Hagan(6), Polina Da Silva(6), James D. Berry(4), Katherine Houghton(3), Abigail Hitchens(3), Agessandro Abrahão(3), Martin Hagan(3), Stephen Apple(3), Kayla Janovsky Ortlip(3), Karen L. M. Martin(3), Benjamin Rix Brooks(2), Gustavo Suarez Zambrano(2), Kyle Paret(2), Jeffrey Zhang(2), Antoinette Harrison(2), Jack Wright(2), Nathan Ball(2), Halima Iqbal(2)